Drug:
Reaction: GENERAL PHYSICAL HEALTH DETERIORATION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555536 |
EU |
59 | |
Lymphoma, Testicular neoplasm, Richter^s syndrome, Submandibular gland enlargement, Dysphonia, Stress, General physical health deterioration, Pain in extremity, Night sweats, Dyspnoea, Dyspnoea, Asthenia, Off label use, |
||||
RITUXIMAB, VENETOCLAX, PIRTOBRUTINIB, |
||||
| 2 | 26555616 |
CA |
1 | |
General physical health deterioration, Dyspnoea, |
||||
PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 3 | 26556199 |
EU |
56 | |
Cardio-respiratory arrest, Pancytopenia, Encephalitis, Malnutrition, Diarrhoea, Weight decreased, Neurological decompensation, General physical health deterioration, |
||||
| 4 | 26556457 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 5 | 26556634 |
CN |
1 | |
Death, Nausea, Pallor, Tremor, Disease recurrence, Decreased appetite, Fatigue, Nasopharyngitis, Metastases to liver, Pulmonary mass, Neoplasm progression, General physical health deterioration, Gait disturbance, Somnolence, Confusional state, |
||||
TRASTUZUMAB, TRASTUZUMAB, OXALIPLATIN, OXALIPLATIN, CAPECITABINE, CAPECITABINE, |
||||
| 6 | 26557156 |
CO |
2 | |
Seizure, General physical health deterioration, Depressed mood, Weight decreased, Decreased appetite, Anxiety, |
||||
PANITUMUMAB, |
||||
| 7 | 26557992 |
CO |
71 | 2 |
Diarrhoea, Somnolence, Hypotension, Hospitalisation, Decreased appetite, Gait disturbance, General physical health deterioration, Decreased immune responsiveness, Aphthous ulcer, Dysarthria, Haemoglobin decreased, Abdominal discomfort, |
||||
PANITUMUMAB, |
||||
| 8 | 26559096 |
GB |
||
Death, Cytokine release syndrome, General physical health deterioration, Rash, Nausea, |
||||
TEBENTAFUSP, |
||||
| 9 | 26559348 |
CA |
78 | 1 |
Balance disorder, General physical health deterioration, Chills, Gait disturbance, Pyrexia, |
||||
RITUXIMAB, VINCRISTINE SULFATE, LACTULOSE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MOMETASONE FUROATE, MOMETASONE, NITROGLYCERIN, PANTOPRAZOLE, PREDNISONE, PROCHLORPERAZINE, ROSUVASTATIN, SENNOSIDES, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ALLOPURINOL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CALCIUM CARBONATE, ANTACID, CELECOXIB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, DOXORUBICIN, FILGRASTIM, |
||||
| 10 | 26559373 |
GB |
2 | |
Lower respiratory tract infection, Illness, Tender joint count increased, General physical health deterioration, |
||||
METHOTREXATE SODIUM, SECUKINUMAB, |
||||
| 11 | 26559952 |
CA |
40 | 2 |
Blepharospasm, Bursitis, C-reactive protein increased, Decreased appetite, Depression, Diarrhoea, Discomfort, Dizziness, Duodenal ulcer perforation, Epilepsy, General physical health deterioration, Grip strength decreased, Hand deformity, Headache, Live birth, Hepatic enzyme increased, Hypoaesthesia, Inflammation, Infusion related reaction, Joint swelling, Type 2 diabetes mellitus, |
||||
SECUKINUMAB, DICLOFENAC SODIUM, CANDESARTAN, LEFLUNOMIDE, MAGNESIUM, RITUXIMAB, ERENUMAB-AOOE, OXYCODONE HYDROCHLORIDE, OXYCODONE, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, ERENUMAB-AOOE, DICLOFENAC, DICLOFENAC SODIUM, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, DICLOFENAC SODIUM, |
||||
| 12 | 26560307 |
US |
67 | |
Disability, Diarrhoea, Dehydration, Fatigue, General physical health deterioration, Mental disorder, Drug intolerance, |
||||
LINACLOTIDE, |
||||
| 13 | 26561064 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 14 | 26550164 |
EU |
17 | 2 |
Anal ulcer, Large intestinal stenosis, Genital abscess, Colitis, Anal abscess, Anal stenosis, Drug ineffective, Proctalgia, Rectal tenesmus, Secretion discharge, General physical health deterioration, Abdominal pain, Diarrhoea, Female genital tract fistula, Weight decreased, Dyschezia, Female genital tract fistula, Anal fistula, |
||||
USTEKINUMAB, INFLIXIMAB, ADALIMUMAB, VEDOLIZUMAB, AZATHIOPRINE, |
||||
| 15 | 26550639 |
CA |
65 | 2 |
Oesophageal obstruction, Abdominal pain, Fatigue, Aphonia, Blood pressure decreased, Stoma site pain, Feeling of body temperature change, General physical health deterioration, Stoma site erythema, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, HYDROMORPHONE HYDROCHLORIDE, |
||||
| 16 | 26551090 |
IN |
66 | 2 |
General physical health deterioration, Hepatic pain, Gait disturbance, Decreased appetite, Drug ineffective, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 17 | 26551301 |
41 | 1 | |
Dizziness, Peripheral swelling, Joint swelling, General physical health deterioration, |
||||
RIOCIGUAT, AMBRISENTAN, TREPROSTINIL, |
||||
| 18 | 26551521 |
CA |
1 | |
Dyspnoea, General physical health deterioration, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 19 | 26551561 |
CA |
63 | 2 |
Adenocarcinoma of the cervix, Cervix carcinoma stage IV, Myocarditis, General physical health deterioration, Myopathy, Drug-induced liver injury, Myasthenia gravis, |
||||
CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), DOSTARLIMAB, |
||||
| 20 | 26551928 |
US |
50 | 2 |
Pain, General physical health deterioration, |
||||
ABATACEPT, ADALIMUMAB-ADAZ, |
||||
| 21 | 26551958 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 22 | 26551960 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 23 | 26551961 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 24 | 26552007 |
EU |
69 | 1 |
General physical health deterioration, Hydronephrosis, Klebsiella infection, |
||||
| 25 | 26552288 |
KR |
||
Organ failure, General physical health deterioration, |
||||
TEPOTINIB HYDROCHLORIDE, |
||||
| 26 | 26552582 |
GB |
26 | 2 |
General physical health deterioration, Loss of consciousness, Multiple acyl-coenzyme A dehydrogenase deficiency, Acute kidney injury, Rhabdomyolysis, Pain in extremity, Food intolerance, Immobile, Abdominal distension, Dysphagia, Hypoaesthesia, Nausea, Alopecia, Vomiting, Rash, Paraesthesia, |
||||
SERTRALINE, |
||||
| 27 | 26553390 |
US |
60 | 1 |
General physical health deterioration, |
||||
DAPAGLIFLOZIN, |
||||
| 28 | 26553406 |
AU |
65 | 1 |
General physical health deterioration, Asthenia, Diverticulitis, Free prostate-specific antigen decreased, |
||||
TRIPTORELIN PAMOATE, |
||||
| 29 | 26553467 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 30 | 26553873 |
CA |
80 | 2 |
Death, Renal impairment, Renal impairment, Product dose omission issue, Wheelchair user, General physical health deterioration, Therapy interrupted, |
||||
| 31 | 26554246 |
US |
67 | 1 |
Somnolence, General physical health deterioration, Product quality issue, Patient dissatisfaction with treatment, Drug ineffective, Flushing, Asthenia, Blood glucose fluctuation, |
||||
METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, REPAGLINIDE, |
||||
| 32 | 26554581 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 33 | 26554640 |
GB |
35 | 1 |
Surgery, General physical health deterioration, |
||||
UPADACITINIB, |
||||
| 34 | 26554673 |
US |
1 | |
Loss of consciousness, General physical health deterioration, Gait disturbance, Loss of employment, Tremor, Impaired driving ability, Somnolence, Adverse event, |
||||
RAVULIZUMAB, |
||||
| 35 | 26554680 |
CO |
54 | 1 |
Diarrhoea, Body temperature abnormal, General physical health deterioration, Fatigue, |
||||
RAVULIZUMAB, RAVULIZUMAB, ECULIZUMAB, ECULIZUMAB, |
||||
| 36 | 26554865 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 37 | 26554897 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 38 | 26554920 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 39 | 26555100 |
AR |
76 | 1 |
Liver operation, General physical health deterioration, Gastrointestinal disorder, Acne, Rash, Procedural pain, |
||||
PANITUMUMAB, |
||||
| 40 | 26558695 |
81 | 1 | |
Pneumonia aspiration, Mobility decreased, Fall, Dysphagia, Confusional state, Dysstasia, Gait disturbance, Speech disorder, Tremor, General physical health deterioration, |
||||
BREXPIPRAZOLE, ERGOCALCIFEROL, AMLODIPINE, LOSARTAN, RIVASTIGMINE, |
||||
| 41 | 26549629 |
US |
35 | 2 |
Injection site bruising, General physical health deterioration, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, |
||||
| 42 | 26546840 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 43 | 26546869 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 44 | 26546930 |
EU |
77 | 2 |
Hyponatraemia, Confusional state, Hallucination, General physical health deterioration, Device physical property issue, |
||||
DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), AMLODIPINE BESYLATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, FOLIC ACID, SERTRALINE HYDROCHLORIDE, ROTIGOTINE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, OPICAPONE, AMLODIPINE BESYLATE, |
||||
| 45 | 26547041 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 46 | 26547181 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 47 | 26547376 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 48 | 26547668 |
EU |
1 | |
Gait disturbance, Bradykinesia, General physical health deterioration, Resting tremor, Balance disorder, Fine motor skill dysfunction, Dysarthria, Hallucination, visual, Vitamin D deficiency, Folate deficiency, Benign prostatic hyperplasia, Cognitive disorder, Depressed mood, Gait inability, Urinary retention, Dysarthria, Dysarthria, Ataxia, Hypothyroidism, Anal incontinence, Restlessness, Agitation, |
||||
ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, OXYBUTYNIN, TORSEMIDE, QUETIAPINE, |
||||
| 49 | 26548261 |
US |
69 | 2 |
Cataract, Cough, General physical health deterioration, Fatigue, Oedema peripheral, Diarrhoea, Headache, Fluid retention, Dialysis related complication, Product supply issue, Device operational issue, Product dose omission issue, Product use complaint, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, SILDENAFIL CITRATE, SILDENAFIL, AMBRISENTAN, MACITENTAN, AMLODIPINE BESYLATE, CALCIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ERGOCALCIFEROL, WARFARIN SODIUM, WARFARIN, BIOTIN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, BUMETANIDE, ALBUTEROL SULFATE, OXYGEN, 0XYGEN, ERGOCALCIFEROL, FOLIC ACID, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, FERROUS SULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, SOTATERCEPT-CSRK, EMPAGLIFLOZIN, |
||||
| 50 | 26548441 |
CO |
69 | 1 |
Syncope, Loss of consciousness, Muscle rigidity, Drug effect less than expected, Influenza like illness, Lethargy, Defaecation urgency, Abdominal discomfort, Gait disturbance, General physical health deterioration, Decreased appetite, Asthenia, |
||||
VEDOLIZUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FOLIC ACID, IRON, PRAZOSIN, AZATHIOPRINE, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, |
||||
| 51 | 26543005 |
US |
43 | 2 |
Rheumatoid arthritis, Asthenia, General physical health deterioration, Ill-defined disorder, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 52 | 26543009 |
37 | 1 | |
Depressed level of consciousness, Asthenia, Aphonia, General physical health deterioration, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 53 | 26543018 |
EU |
37 | 2 |
General physical health deterioration, Abortion induced, Maternal exposure during pregnancy, |
||||
CYANOCOBALAMIN, |
||||
| 54 | 26543057 |
EU |
1 | |
Malaise, Loss of consciousness, Seizure, Encephalitis herpes, General physical health deterioration, Epilepsy, Craniofacial fracture, Fall, Off label use, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, DALFAMPRIDINE, |
||||
| 55 | 26543146 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 56 | 26543184 |
CA |
43 | 2 |
Abdominal discomfort, Abdominal pain, Abdominal pain upper, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Breast cancer stage III, Condition aggravated, Confusional state, Duodenal ulcer perforation, Epilepsy, Facet joint syndrome, Fibromyalgia, General physical health deterioration, Helicobacter infection, Lip dry, Liver injury, Lower respiratory tract infection, Lung disorder, Maternal exposure timing unspecified, Memory impairment, Migraine, Muscle injury, Muscle spasms, Musculoskeletal pain, Nail disorder, Osteoarthritis, Paraesthesia, Pemphigus, Pericarditis, Psoriatic arthropathy, Rash, Rheumatoid arthritis, Stomatitis, Swelling, Systemic lupus erythematosus, Taste disorder, Type 2 diabetes mellitus, Wound infection, |
||||
TOCILIZUMAB, RITUXIMAB, LORAZEPAM, CALCIUM GLUCONATE, CYANOCOBALAMIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 57 | 26543292 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 58 | 26543334 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 59 | 26543349 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 60 | 26543408 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 61 | 26543423 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 62 | 26543449 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 63 | 26543628 |
EU |
72 | 1 |
Death, General physical health deterioration, |
||||
| 64 | 26543664 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 65 | 26543968 |
US |
55 | 2 |
Pain, General physical health deterioration, Off label use, |
||||
ABATACEPT, |
||||
| 66 | 26544174 |
EU |
15 | 2 |
General physical health deterioration, Aphasia, Dyskinesia, Aggression, |
||||
LACOSAMIDE, LACOSAMIDE, LACOSAMIDE, BRIVARACETAM, BRIVARACETAM INJECTION, BRIVARACETAM, BRIVARACETAM INJECTION, BRIVARACETAM, BRIVARACETAM INJECTION, METHYLPREDNISOLONE, |
||||
| 67 | 26544330 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 68 | 26544543 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 69 | 26544571 |
EU |
2 | |
General physical health deterioration, Adrenal insufficiency, Depression, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 70 | 26544813 |
US |
60 | 2 |
Pain, General physical health deterioration, |
||||
ABATACEPT, ADALIMUMAB-ADAZ, |
||||
| 71 | 26545216 |
EU |
59 | 1 |
Lymphoma, Testicular neoplasm, Richter^s syndrome, Submandibular gland enlargement, Dysphonia, Night sweats, Stress, General physical health deterioration, Dyspnoea exertional, Dyspnoea, Pain in extremity, Off label use, Asthenia, |
||||
PIRTOBRUTINIB, VENETOCLAX, RITUXIMAB, |
||||
| 72 | 26545308 |
43 | ||
Abdominal discomfort, Abdominal pain, Abdominal pain upper, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Breast cancer stage III, Condition aggravated, Confusional state, Duodenal ulcer perforation, Epilepsy, Facet joint syndrome, Fibromyalgia, General physical health deterioration, Helicobacter infection, Lip dry, Liver injury, Lower respiratory tract infection, Lung disorder, Maternal exposure during pregnancy, Memory impairment, Migraine, Muscle injury, Muscle spasms, Musculoskeletal pain, Nail disorder, Osteoarthritis, Paraesthesia, Pemphigus, Pericarditis, Psoriatic arthropathy, Rash, Rheumatoid arthritis, Stomatitis, Swelling, Systemic lupus erythematosus, Taste disorder, Type 2 diabetes mellitus, Wound infection, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN AND CODEINE, TOCILIZUMAB, ERENUMAB-AOOE, LEFLUNOMIDE, ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE, BOTULINUM TOXIN TYPE A, BUPRENORPHINE, CANDESARTAN, CELECOXIB, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, SECUKINUMAB, DESOXIMETASONE, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, ETANERCEPT, ETANERCEPT, FOLIC ACID, ALENDRONATE SODIUM, GOLD, HYDROCORTISONE BUTYRATE, HYDROXYCHLOROQUINE SULFATE, ADALIMUMAB-ADAZ, LAMOTRIGINE, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, MIRABEGRON, OXYCODONE, RITUXIMAB, APREMILAST, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, TRAMADOL HYDROCHLORIDE, LORAZEPAM, CYANOCOBALAMIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 73 | 26545322 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 74 | 26546087 |
EU |
48 | 1 |
Disseminated nocardiosis, Brain abscess, Cytomegalovirus infection reactivation, Giardiasis, Cytopenia, Urinary retention, Pericardial effusion, General physical health deterioration, Asthenia, Decreased appetite, Productive cough, Chest pain, Motor dysfunction, Skin mass, Lung consolidation, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 75 | 26546568 |
US |
75 | 1 |
Illness, General physical health deterioration, |
||||
POMALIDOMIDE, |
||||
| 76 | 26546713 |
CO |
5 | 2 |
General physical health deterioration, Decreased appetite, Weight decreased, Developmental delay, Drug ineffective, |
||||
CERLIPONASE ALFA, LAMOTRIGINE, CLOBAZAM, |
||||
| 77 | 26558220 |
29 | 2 | |
Withdrawal syndrome, Formication, Skin burning sensation, Insomnia, Intrusive thoughts, Panic disorder, Affect lability, Photophobia, Hyperacusis, Disturbance in attention, Communication disorder, Hyperhidrosis, Cardiac disorder, Endocrine disorder, Hormone level abnormal, Pain, Muscular weakness, Impaired healing, Emotional distress, Depression, Disability, Crying, Loss of personal independence in daily activities, Impaired quality of life, General physical health deterioration, Myalgia, Arthralgia, Anxiety, Diarrhoea, Blindness, Akathisia, Parosmia, Tremor, |
||||
CLONAZEPAM, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, MAGNESIUM, ERGOCALCIFEROL, SAFFRON, |
||||
| 78 | 26535846 |
US |
1 | |
Death, General physical health deterioration, Device issue, |
||||
FOSCARBIDOPA/FOSLEVODOPA, |
||||
| 79 | 26535849 |
CA |
80 | 2 |
Hepatic cirrhosis, Weight decreased, Asthenia, Mobility decreased, Oedema peripheral, Bedridden, Gait inability, General physical health deterioration, |
||||
ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, |
||||
| 80 | 26535858 |
EU |
75 | 2 |
Decubitus ulcer, General physical health deterioration, Weight decreased, |
||||
FOSCARBIDOPA/FOSLEVODOPA, |
||||
| 81 | 26536309 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 82 | 26536447 |
IN |
1 | |
Drug-induced liver injury, Ascites, General physical health deterioration, Dyspnoea, |
||||
DURVALUMAB, |
||||
| 83 | 26536502 |
CA |
78 | 2 |
Aspiration, Abdominal pain upper, Upper respiratory tract infection, Pneumonia, Pulmonary fibrosis, Lower respiratory tract infection, Hypoxia, Bronchiectasis, Anaemia, Asthma, Blood calcium increased, Blood test abnormal, Bronchopulmonary aspergillosis allergic, Gastrooesophageal reflux disease, Haemoptysis, Lung opacity, Musculoskeletal stiffness, Obstructive airways disorder, Pleural effusion, Rales, Sputum discoloured, Total lung capacity decreased, Wheezing, Pain, General physical health deterioration, Pulmonary mass, Dyspnoea, Oedema peripheral, Pyrexia, Constipation, Asthenia, Fatigue, Tremor, Headache, Blood creatinine increased, Transaminases increased, Liver function test increased, Drug hypersensitivity, Cough, Product dose omission issue, Drug ineffective, Drug ineffective, |
||||
QUETIAPINE FUMARATE, QUETIAPINE, ROSUVASTATIN CALCIUM, CANDESARTAN CILEXETIL, DEXLANSOPRAZOLE, LANSOPRAZOLE, MORPHINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, EFINACONAZOLE, NITROGLYCERIN, BUDESONIDE, |
||||
| 84 | 26536552 |
CA |
43 | 2 |
Abdominal pain, Abdominal pain upper, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Breast cancer stage III, Condition aggravated, Confusional state, Duodenal ulcer perforation, Epilepsy, Facet joint syndrome, Fibromyalgia, General physical health deterioration, Helicobacter infection, Lip dry, Liver injury, Lower respiratory tract infection, Lung disorder, Maternal exposure timing unspecified, Memory impairment, Migraine, Muscle injury, Muscle spasms, Musculoskeletal pain, Nail disorder, Osteoarthritis, Paraesthesia, Pemphigus, Pericarditis, Psoriatic arthropathy, Rash, Rheumatoid arthritis, Stomatitis, Swelling, Systemic lupus erythematosus, Taste disorder, Type 2 diabetes mellitus, Wound infection, |
||||
TOCILIZUMAB, RITUXIMAB, LORAZEPAM, CYANOCOBALAMIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 85 | 26536583 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 86 | 26536660 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 87 | 26536758 |
JP |
6 | 1 |
General physical health deterioration, Platelet count decreased, Diarrhoea, |
||||
FRUQUINTINIB, |
||||
| 88 | 26536824 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 89 | 26537169 |
CA |
96 | 2 |
Gastrointestinal disorder, Gastrooesophageal reflux disease, General physical health deterioration, Glossodynia, Grip strength decreased, Hand deformity, Headache, Hepatic cirrhosis, Underdose, Helicobacter infection, Hypercholesterolaemia, Hypersensitivity, Hypertension, Ill-defined disorder, Impaired healing, Intentional product use issue, Hepatic enzyme increased, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, APREMILAST, APREMILAST, CANDESARTAN, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, OXYCODONE, OXYCODONE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, CYCLOBENZAPRINE, INFLIXIMAB, INFLIXIMAB, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, GOLIMUMAB, USTEKINUMAB, PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, ABATACEPT, MEPOLIZUMAB, NAPROXEN, NAPROXEN SODIUM, NAPROXEN, NAPROXEN SODIUM, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE, HYDROMORPHONE HYDROCHLORIDE, GOLIMUMAB, GOLIMUMAB, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE, BETAMETHASONE DIPROPIONATE, |
||||
| 90 | 26537282 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 91 | 26537283 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 92 | 26537328 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 93 | 26537401 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 94 | 26537453 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 95 | 26537490 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 96 | 26537492 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 97 | 26537493 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 98 | 26537605 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 99 | 26537634 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 100 | 26537850 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28